Deal abstention ahead if Valeant's $2.6bn bid for Medicis proceeds
This article was originally published in Scrip
Executive Summary
Acquisitive Valeant Pharmaceuticals International will have to put its big ticket purchases on hold for 12 months if it succeeds in pulling off its planned $2.6 billion acquisition of US dermatology and aesthetics firm Medicis.